Insmed posts Phase 2a results for OpSCF in moderate to severe atopic dermatitis
Results were first posted September 11, 2026, for a completed 50-patient trial testing the monoclonal antibody OpSCF against placebo.
The week's activity centers on results reporting for one completed Insmed atopic dermatitis study.
- Insmed's Phase 2a trial (NCT06101823, "OpSCF-201") testing OpSCF, a monoclonal antibody, in adults with moderate to severe atopic dermatitis, has posted results as of September 11, 2026. The study was completed with a study completion date of 2025-08-18, and its primary purpose was to evaluate efficacy and safety of OpSCF compared to placebo.1 Enrollment reached 50 participants in a randomized, quadruple-masked, parallel design.1 The primary outcome measure was percent change from baseline in Eczema Area and Severity Index (EASI) at Week 16.1 Participants who completed the placebo-controlled period could enter an Open Label Extension phase in which all subjects received OpSCF every 4 weeks for 40 additional weeks.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.